Acute Respiratory Failure
Conditions
Keywords
COVID-19, Acute respiratory failure, ARDS
Brief summary
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN) response has been demonstrated in patients with severe COVID-19, together with a high viral load. The aim of the current work is, in a large cohort of patients with severe COVID-19 admitted in the ICU, to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome, as compared to patients having negative anti-IFN antibodies.
Detailed description
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN) response has been demonstrated in patients with severe COVID-19, together with a high viral load. A recent study revealed that 10% of patients admitted in the intensive care unit (ICU) for severe COVID-19 had positive type I anti-IFN antibodies. Such finding has potentially important therapeutic implications, as patients having positive anti-IFN antibodies could benefit from targeted interventions, including plasmapheresis. The aim of the current work is, in a large cohort of patients with severe COVID-19 admitted in the ICU, to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome, as compared to patients having negative anti-IFN antibodies.
Interventions
None listed
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Age ≥ 18 years * SARS-CoV-2 infection with a positive PCR * Patient admitted in the ICU for acute respiratory failure (SpO2≤90% and need for supplemental oxygen or any kind of ventilator support) * Patient or next of keen was informed of study inclusion
Exclusion criteria
• Patient with SARS-CoV-infection but no acute respiratory failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| day-28 mortality | at day-28 of intensive care unit (ICU) admission | comparaison of day-28 mortality in patients having positive versus negative type I anti-IFN antibodies |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of positivity of type I anti-IFN antibodies | 3 months of ICU admission | positivity of type I anti-IFN antibodies measured on a serum sample obtained at any time during ICU stay |
| Factors associated with type I anti-IFN antibody positivity | 24 hours of ICU admission | Factors associated with type I anti-IFN antibody positivity available upon hospital admission, identified using uni- and multiple logistic regression analyses |
| hospital mortality | at day 90. | Comparaison of hospital mortality of patients having positive versus negative type I anti-IFN antibodies |
Countries
France
Outcome results
None listed